DKDaisuke Kobayashi

Daisuke Kobayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daisuke Kobayashi has a total of 194 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas J. Forbes

    Division of Cardiology, Joe DiMaggio Children's Hospital, Hollywood, Florida

    28 shared publications
  • Sanjeev Aggarwal

    Division of Cardiology, Children's Hospital of Michigan, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA

    14 shared publications
  • Daniel R. Turner

    Division of Cardiology, Children’s Hospital of Michigan, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA

    11 shared publications
  • Christopher Herron

    Department of Pediatric Cardiology, Arnold Palmer Hospital for Children, Orlando, USA

    9 shared publications
  • Henry L. Walters

    Division of Cardiovascular Surgery, Children's Hospital of Michigan, Department of Surgery, Wayne State University School of Medicine, Detroit, MI, USA

    7 shared publications
  • Robert D. Ross

    Division of Cardiology, Children's Hospital of Michigan, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, 3901 Beaubien Blvd, Detroit 48201-2119, MI, USA

    7 shared publications

Latest Publications

  • Open Access

    Postapproval Study Outcomes of Muscular Ventricular Septal Defect Closure With the Amplatzer Muscular VSD Occluder

    by Athar M. Qureshi, Henri Justino, Carl Owada, Mohammed Numan, Makram Ebeid, Thomas J. Forbes, David Nykanen, Daisuke Kobayashi, Jillian Kolles, Dan Gutfinger, et al.

    BACKGROUND: The Amplatzer Muscular Ventricular Septal Defect (VSD) Occluder (Abbott Structural Heart, Plymouth, MN) was approved by the US Food and Drug Administration in 2007. As a condition of approval, a postapproval study was required to further evaluate its safety and effectiveness. This study reports the clinical outcomes from the postapproval study over 5 years of follow-up. METHODS: Patients with complex congenital muscular VSDs at high risk for surgical closure were enrolled between May 2008 and February 2020 in the United States and Canada. The primary effectiveness end points were technical implant success, acute procedure shunt-closure success, and 1-year shunt-closure success. The primary safety end point was the proportion of patients with any serious adverse event within 12 months of the procedure. RESULTS: A total of 92 patients (median age, 2 years; 50 females) were enrolled in the study. Technical implant success was achieved in 93.8% of patients, and acute shunt-closure success was achieved in 78.0%. Successful shunt closure at 1-year was 94.4% and increased to >98% between 2 and 5 years. Within 12 months of the procedure, all-cause serious adverse events occurred in 47 of the 90 (52.2%) patients which included 7 device-related and 23 procedure-related serious adverse events. Between 1 and 5 years, there was 1 additional device- and procedure-related serious adverse event. CONCLUSIONS: This postapproval study demonstrates that transcatheter muscular VSD closure with the Amplatzer Muscular VSD Occluder is a safe and effective therapy for the treatment of complex congenital muscular VSDs in patients who are at high-risk for surgical closure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00647387.

  • Incidence of High Severity Anesthesia Related Adverse Events With Increasing PREDIC 3 T Risk Category in Congenital Cardiac Catheterization: A Review of the C3PO Database

    by Kristin Chenault, Grace R. Rahman, Kimberlee Gauvreau, Juan Ibla, Daisuke Kobayashi, Bridget Pearce, Brian Quinn, Ruchik Sharma, Justinn Tanem, Jessica Tang, et al.

    Background: Safe and effective anesthesia is critical for the care of pediatric patients with congenital heart disease undergoing cardiac catheterization. Over the past two decades, there has been a significant transition from primarily diagnostic procedures to complex interventional cases, accompanied by a shift from operator‐managed sedation to anesthesia administered by a trained anesthesiologist. Aims: The aim of our study is to explore the incidence of high severity anesthesia related adverse events (ARAE) and whether these rates correlate with Procedural Risk in Congenital Cardiac Catheterization (PREDIC 3 T) case‐type risk categories. Higher risk categories have been shown to correlate with high severity procedural related adverse events. Methods: A multicenter, retrospective cohort study utilized data collected prospectively in the Congenital Cardiac Catheterization Project on Outcomes (C3PO). This study, encompassing 18 contributing institutions, analyzed data from January 1, 2019 to December 31, 2023. Rates of 17 specific ARAE were stratified via PREDIC 3 T category. Results: During the study period, 38, 021 cardiac catheterizations were included in this analysis. A total of 321 ARAE of any severity (level 1–5) were recorded, for an overall rate of 0.8% (CI, 0.7%–0.9%). Of these 321 ARAE, 160 were high severity (level 3bc/4/5), yielding a rate of 0.4%. Rates of high severity ARAE by PREDIC 3 T risk category (0,1, 2, 3, 4, 5) were found to be 0.2%. 0.4%, 0.5%, 0.3%. 0.8%, and 0.7%, respectively. Multivariable logistic regression analyses identified weight under 10 kg, hemodynamic vulnerability score (HVS) ≥ 1, and PREDIC 3 T risk category 5 procedures as factors associated with higher odds of experiencing a high severity ARAE. Conclusions: The overall rate of ARAE, including high severity ARAE, was found to be increased in higher PREDIC 3 T risk category procedures. Both patient and procedural factors contribute to ARAE in the congenital cardiac catheterization laboratory. Clinical Trial Number and Registry: Not applicable.


  • Transcatheter Main Pulmonary Artery Debanding in Children—Immediate and Midterm Outcomes

    by Hadeel Allam, Daisuke Kobayashi, Dominic B. Zanaboni, Andrew C. Glatz, Pirooz Eghtesady, Ramzi Nicolas, David T. Balzer

    Background: Surgical main pulmonary artery (PA) banding is a palliative procedure to regulate pulmonary blood flow in patients with ventricular septal defects (VSD)(s). Aims: We report on immediate and midterm outcomes of transcatheter PA debanding. Methods: Single‐center retrospective case series of children who underwent transcatheter debanding between 2017 and 2025. Baseline clinical and follow‐up data were reviewed. Results: Nine patients underwent transcatheter debanding at a median age of 9 months (Q1−Q3, 7–13) and a median weight of 8.0 kg (7.3–10.3). Surgical PA bands were placed for large or multiple VSDs, with or without aortic coarctation repair. Median time from banding to debanding was 6 months (9−13). Before debanding, right ventricular (RV) systolic pressure was 115% (84−126) of systemic pressure, and the peak right ventricle‐to‐PA (RV‐PA) echocardiographic gradient was 76 mmHg (72−100). Debanding was performed using a balloon‐to‐angiographic band diameter ratio of 2.3 (2−3.1) and a balloon to angiographic pulmonary valve annulus ratio of 0.93 (0.90–1.02). Post debanding, RV systolic pressure and RV‐PA gradient improved to 72% (62−75, p < 0.05) of the systemic pressure and 36 mmHg (30−46; p < 0.05), respectively. Band diameter increased from 4.6 mm (4.5−5.1) to 9.3 mm (8.3‐11.0; p < 0.05). There were no major procedural complications. Peak RV‐PA gradients remained low at 23 mmHg (12−51) at a median follow‐up of 2 years (1−2.4). One patient required repeat balloon angioplasty, and one underwent surgical debanding along with VSD closure. Conclusion: Transcatheter PA debanding is safe and effective in selected patients, with sustained low echocardiography gradients in mid‐term follow‐up.

  • Open Access

    Trends in Radiation Exposure With the Refinement of Radiation Exposure Categories in Congenital Cardiac Catheterization: Insights From the CRISP Registry

    by Gurumurthy Hiremath, Juan Carlos Samayoa, Alexander Javois, Osamah Aldoss, Ryan Leahy, Reid Chamberlain, Elena Amin, Marko Vezmar, Makram Ebeid, Shyam Sathanandam, et al.


  • Significant Practice Variation in Oxygen Consumption Values in Congenital Cardiac Catheterization: Cross Sectional Survey in the United States

    by Daisuke Kobayashi, Dominic B. Zanaboni, Andrew C. Glatz, David Balzer

    Oxygen consumption (VO2) is an essential component to calculate cardiac output using the Fick principle in the congenital cardiac catheterization laboratory (CCCL). Although VO2 can be measured, the value of VO2 is frequently assumed based on predictive equations. The objective of this study was to investigate current practice variation in measurement and estimation of VO2 in CCCL. This was a cross-sectional survey study conducted in January–February 2024. The survey (n = 114) was sent to one interventional cardiologist for each CCCL program in the United States utilizing REDCap. The responses were summarized in a descriptive fashion. Eighty eight programs completed the survey (response rate 77%). Only 13 (15%) programs measured VO2, though 67 programs (76%) thought VO2 should be measured for all cases (n = 41) and selective cases (n = 26) and 17 programs thought assumed VO2 was satisfactory. When VO2 is referred from predictive equations, most programs primarily used LaFarge (n = 64, 73%), followed by Seckeler (n = 23, 26%). For patients aged < 3 years (where LaFarge equation does not provide VO2 value) in 64 programs using LaFarge, 16 used Seckeler and the remaining 48 programs used a wide range of arbitrary VO2 values. Most CCCL thought VO2 should be measured but only 13 (15%) programs actually measured VO2 in the United States. LaFarge remains frequently used as a predictive equation. There is no standardization of clinical practice in VO2 measurement/estimation among CCCL in the United States.


  • Usefulness of PREDIC3T Case Type Risk Category in the CRISP Registry

    by Daisuke Kobayashi, Elena K. Amin, Gareth J. Morgan, Surendranath R. Veeram Reddy, Gregory A. Fleming, Thomas J. Forbes, David G. Nykanen


  • Open Access

    Interventions to prevent hypothermia in extremely preterm low-weight infants undergoing cardiac catheterisation

    by Eliane Alhalabi, Maria Zestos, Daisuke Kobayashi, George M Mckelvey, Rachel A Taylor

    Background In January 2019, a new device called the Amplatzer Piccolo Occluder was approved by the US Food and Drug Administration for percutaneous closure of patent ductus arteriosus in infants weighing more than 700 g and of postnatal age more than 3 days. Premature low-weight infants are predisposed to hypothermia when transported outside of the thermo-neutral environment. At our institution, 90% of extremely preterm low-weight infants developed transient moderate hypothermia in the cardiac catheterisation suite. Methods We conducted a study testing multiple hypotheses aimed at preventing hypothermia in the cardiac catheterisation suite. Interventions included increasing ambient room temperature, reducing exposure to cold environment and reducing overall time spent in the remote location. The primary outcome was the proportion of patients who developed transient hypothermia at the start of the procedure in the cardiac catheterisation suite. The secondary measures included mean core body temperature at four different instances, as well as anaesthesia time, procedure time and radiation exposure. Results During the study period, 10 patients were enrolled in each group. The postintervention group saw a reduction in transient hypothermia from 90% to 40% (absolute risk reduction 50%, p=0.02). Data analysis showed an improvement in mean core body temperature (35.4°C vs 36.4°C, pConclusion The application of the interventions reduced hypothermia in this high-risk population. The implementation of a protocol with collaboration of a multidisciplinary team is indispensable in providing optimal care to extremely preterm infants.